52Q0 Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EST
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €1.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€7.61M
Enterprise Value€380.03
Total Cash (Recent Filing)€19.51M
Total Debt (Recent Filing)€240.41M
Price to Earnings (P/E)―
Beta7.86
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding1,482,451,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00073
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe sharp TTM revenue expansion indicates improving commercial traction and a larger operating base. If sustained, this growth can support better fixed-cost absorption and provide a foundation for eventual margin improvement.
Improved Operating Cash FlowA move to positive operating cash flow suggests that core activities are generating more cash than in the prior period. Continued improvement would reduce reliance on external funding and strengthen the company’s ability to finance operations.
Positive Equity And Moderate LeveragePositive equity and moderate TTM leverage provide some balance-sheet support while the business scales. This offers greater financial flexibility than a highly levered structure, although the position remains sensitive to continued losses and debt growth.
Bears Say
Severe Operating LossesVery large operating and net losses show that costs substantially exceed current revenue, limiting the durability of the growth model. Persistent losses could require restructuring, additional capital, or slower expansion until operating leverage improves.
Negative Free Cash FlowDespite positive operating cash flow, negative free cash flow means the company is not yet fully funding investment and other cash needs internally. If this persists, ongoing external financing may be required, increasing dilution or refinancing risk.
Rising Debt And Balance-Sheet VolatilityThe sharp increase in debt and history of negative equity indicate a volatile capital structure. Higher obligations can constrain future investment and amplify funding pressure, particularly while returns remain negative and losses continue.
52Q0 FAQ
What was AegirBio AB’s price range in the past 12 months?
AegirBio AB lowest stock price was <€0.01 and its highest was €1.55 in the past 12 months.
What is AegirBio AB’s market cap?
AegirBio AB’s market cap is €7.61M.
When is AegirBio AB’s upcoming earnings report date?
AegirBio AB’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were AegirBio AB’s earnings last quarter?
AegirBio AB released its earnings results on Aug 20, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is AegirBio AB overvalued?
According to Wall Street analysts AegirBio AB’s price is currently Overvalued.
Does AegirBio AB pay dividends?
AegirBio AB does not currently pay dividends.
What is AegirBio AB’s EPS estimate?
AegirBio AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AegirBio AB have?
AegirBio AB has 1,482,451,200 shares outstanding.
What happened to AegirBio AB’s price movement after its last earnings report?
AegirBio AB reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AegirBio AB?
Currently, no hedge funds are holding shares in DE:52Q0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AegirBio AB
Subgen AI AB develops artificial intelligence-based models and applications to control data for government and businesses. The company engages in the provision of information society services aimed at delivering financial and related knowledge tools to facilitate third-party access to financial literacy and instruments that enable them to interpret such information through e-learning; the acquisition, ownership, management and administration of securities; and the acquisition, ownership, marketing, leasing and operation of rural or urban properties. It also provides financial intermediation services; computer programming activities, structure and content design, writes computer code for systems, computer software, databases and web pages; and customizes computer programs, including configuration and modification of legacy programs. In addition, the company offers marketing and after-sales services of diagnostic imaging machinery and human resources services, as well as development of state-of-the-art artificial intelligence (Al) systems. Further, it provides Serenity Star, AI4D core, and Substrate Cloud. The company is based in London, United Kingdom. Subgen AI AB operates as a subsidiary of Substrate Artificial Inteligence, S.A.